Q32 Bio (QTTB) Capital Expenditures Growth (5y) (2022 - 2025)
Q32 Bio (QTTB) Capital Expenditures Growth (5y) (2022 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | Q32 Bio | 215.80 Mn | 165.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 31.28% |
| Sep 30, 2025 | -24.25% |
| Jun 30, 2025 | 15.87% |
| Mar 31, 2025 | -30.57% |
| Dec 31, 2024 | -58.70% |
| Sep 30, 2024 | 15.30% |
| Jun 30, 2024 | -14.97% |
| Mar 31, 2024 | -53.47% |
| Sep 30, 2023 | -82.00% |
| Jun 30, 2023 | -63.48% |
| Mar 31, 2023 | -23.32% |
| Dec 31, 2022 | -21.35% |
| Sep 30, 2022 | 14.93% |
| Jun 30, 2022 | 20.67% |
| Mar 31, 2022 | -41.33% |